Waypoint Wealth Counsel’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
Waypoint Wealth Counsel's REGN Position: Q2 2026 in Review
Waypoint Wealth Counsel reduced its Regeneron Pharmaceuticals (REGN) stake by 28% in Q2 2026, selling an estimated $210K and leaving 777 shares worth $484K. The position accounts for 0.3% of the portfolio, ranked #57.
Waypoint Wealth Counsel first reported a position in REGN in Q3 2025 and has held it in 4 quarters since. The position peaked at $838K in Q1 2026. 1,336 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Waypoint Wealth Counsel held 777 shares of Regeneron Pharmaceuticals worth $484K as of Q2 2026.
- Waypoint Wealth Counsel sold 308 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $210K.
- Regeneron Pharmaceuticals made up 0.3% of Waypoint Wealth Counsel's portfolio in Q2 2026, its #57 holding.
- Waypoint Wealth Counsel first reported a position in Regeneron Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
- Waypoint Wealth Counsel's Regeneron Pharmaceuticals position peaked at $838K in Q1 2026.
- 1,336 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Waypoint Wealth Counsel's 13F filing for Q2 2026, filed 4 Aug 2026.